Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
9.89
+0.25 (2.59%)
At close: Mar 6, 2026, 4:00 PM EST
9.95
+0.06 (0.61%)
After-hours: Mar 6, 2026, 7:50 PM EST
Relay Therapeutics Employees
Relay Therapeutics had 192 employees as of December 31, 2025. The number of employees decreased by 69 or -26.44% compared to the previous year.
Employees
192
Change (1Y)
-69
Growth (1Y)
-26.44%
Revenue / Employee
$79,974
Profits / Employee
-$1,439,995
Market Cap
1.77B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Vericel | 357 |
| Harmony Biosciences Holdings | 293 |
| Innoviva | 159 |
| AnaptysBio | 136 |
| Olema Pharmaceuticals | 122 |
| Pharvaris | 118 |
| Definium Therapeutics | 106 |
RLAY News
- 1 day ago - Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 2 days ago - Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
- 9 days ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - GlobeNewsWire
- 12 days ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 16 days ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 5 weeks ago - Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism - Seeking Alpha